CWRU Technology Ventures — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats.
BiotechHealthtechMedical DevicesIndianapolis, US
David Kalergis(Executive Officer, Director, Promoter)William Akridge(Director)Peter Barton Hutt(Director)
Synapse Biomedical develops and commercializes neurostimulation medical devices, including the NeuRx Diaphragm Pacing System (DPS), which uses electrical stimulation of the diaphragm to treat chronic respiratory insufficiency in patients with spinal cord injuries and ALS.
BiotechDigital HealthHealthtechMedical DevicesHarrisburg, US
Anthony R Ignagni(Executive Officer, Director)Kiyotaka Mori(Director)Moustapha Diop(Chief Operating Officer)Raymond P Onders(Director)John Krystowski(Director)Anthony R. Ignagni(Co-founder, President & CEO)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.